SPOTLIGHT -
Phase II Study of Rituximab in Combination With Fludarabine in Patients With Chronic Lymphocytic Leukemia
This phase II trial investigated the safety and efficacy of a combined-modality treatment with rituximab (Rituxan) and fludarabine (Fludara) in patients with fludarabine- and anthracycline-naive chronic lymphocytic lymphoma (CLL).